Evotec and Immuneering Collaborates to Develop Novel Candidates for Rare Hereditary Metabolic Diseases
Shots:
- The collaboration is a focus of combining Evotec’s stem cell (“iPSC”) platform with Immuneering’s Artificial Intelligence drug discovery platform for development of therapies
- Additionally- Immuneering’s AI platform fluency will assist in analyzing public and proprietary data- for identification of novel candidates
- AI platform is a drug discovery based technology used to discover & develop single and multi-targeted drugs with molecular-level data
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com